Risk Assessment of Drug-Induced Long QT Syndrome for Some COVID-19 Repurposed Drugs.
Identifieur interne : 000188 ( Main/Exploration ); précédent : 000187; suivant : 000189Risk Assessment of Drug-Induced Long QT Syndrome for Some COVID-19 Repurposed Drugs.
Auteurs : Veronique Michaud [États-Unis, Canada] ; Pamela Dow [États-Unis] ; Sweilem B. Al Rihani [États-Unis] ; Malavika Deodhar [États-Unis] ; Meghan Arwood [États-Unis] ; Brian Cicali [États-Unis] ; Jacques Turgeon [États-Unis, Canada]Source :
- Clinical and translational science [ 1752-8062 ] ; 2021.
Descripteurs français
- KwdFr :
- MESH :
- effets indésirables : Antiviraux, Azithromycine, Hydroxychloroquine.
- induit chimiquement : Syndrome du QT long.
- Appréciation des risques, Humains, Repositionnement des médicaments.
English descriptors
- KwdEn :
- MESH :
- chemical , adverse effects : Antiviral Agents, Azithromycin, Hydroxychloroquine.
- chemically induced : Long QT Syndrome.
- drug therapy : COVID-19.
- Drug Repositioning, Humans, Risk Assessment, SARS-CoV-2.
Abstract
The risk-benefit ratio associated with the use of repurposed drugs to treat severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2)-related infectious coronavirus disease 2019 (COVID-19) is complicated because benefits are awaited, not proven. A thorough literature search was conducted to source information on the pharmacological properties of 5 drugs and 1 combination (azithromycin, chloroquine, favipiravir, hydroxychloroquine, remdesivir, and lopinavir/ritonavir) repurposed to treat COVID-19. A risk assessment of drug-induced long QT syndrome (LQTS) associated with COVID-19 repurposed drugs was performed and compared with 23 well-known torsadogenic and 10 low torsadogenic risk compounds. Computer calculations were performed using pharmacokinetic and pharmacodynamic data, including affinity to block the rapid component of the delayed rectifier cardiac potassium current (IKr ) encoded by the human ether-a-go-go gene (hERG), propensity to prolong cardiac repolarization (QT interval) and cause torsade de pointes (TdP). Seven different LQTS indices were calculated and compared. The US Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) database was queried with specific key words relating to arrhythmogenic events. Estimators of LQTS risk levels indicated a very high or moderate risk for all COVID-19 repurposed drugs with the exception for azithromycin, although cases of TdP have been reported with this drug. There was excellent agreement among the various indices used to assess risk of drug-induced LQTS for the 6 repurposed medications and 23 torsadogenic compounds. Based on our results, monitoring of the QT interval shall be performed when some COVID-19 repurposed drugs are used, as such monitoring is possible for hospitalized patients or with the use of biodevices for outpatients.
DOI: 10.1111/cts.12882
PubMed: 32888379
PubMed Central: PMC7877829
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Risk Assessment of Drug-Induced Long QT Syndrome for Some COVID-19 Repurposed Drugs.</title><author><name sortKey="Michaud, Veronique" sort="Michaud, Veronique" uniqKey="Michaud V" first="Veronique" last="Michaud">Veronique Michaud</name><affiliation wicri:level="2"><nlm:affiliation>Tabula Rasa HealthCare Precision Pharmacotherapy Research & Development Institute, Orlando, Florida, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Tabula Rasa HealthCare Precision Pharmacotherapy Research & Development Institute, Orlando, Florida</wicri:regionArea><placeName><region type="state">Floride</region></placeName></affiliation><affiliation wicri:level="1"><nlm:affiliation>Faculty of Pharmacy, Université de Montréal, Montreal, Quebec, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Faculty of Pharmacy, Université de Montréal, Montreal, Quebec</wicri:regionArea><wicri:noRegion>Quebec</wicri:noRegion></affiliation></author><author><name sortKey="Dow, Pamela" sort="Dow, Pamela" uniqKey="Dow P" first="Pamela" last="Dow">Pamela Dow</name><affiliation wicri:level="2"><nlm:affiliation>Tabula Rasa HealthCare Precision Pharmacotherapy Research & Development Institute, Orlando, Florida, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Tabula Rasa HealthCare Precision Pharmacotherapy Research & Development Institute, Orlando, Florida</wicri:regionArea><placeName><region type="state">Floride</region></placeName></affiliation></author><author><name sortKey="Al Rihani, Sweilem B" sort="Al Rihani, Sweilem B" uniqKey="Al Rihani S" first="Sweilem B" last="Al Rihani">Sweilem B. Al Rihani</name><affiliation wicri:level="2"><nlm:affiliation>Tabula Rasa HealthCare Precision Pharmacotherapy Research & Development Institute, Orlando, Florida, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Tabula Rasa HealthCare Precision Pharmacotherapy Research & Development Institute, Orlando, Florida</wicri:regionArea><placeName><region type="state">Floride</region></placeName></affiliation></author><author><name sortKey="Deodhar, Malavika" sort="Deodhar, Malavika" uniqKey="Deodhar M" first="Malavika" last="Deodhar">Malavika Deodhar</name><affiliation wicri:level="2"><nlm:affiliation>Tabula Rasa HealthCare Precision Pharmacotherapy Research & Development Institute, Orlando, Florida, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Tabula Rasa HealthCare Precision Pharmacotherapy Research & Development Institute, Orlando, Florida</wicri:regionArea><placeName><region type="state">Floride</region></placeName></affiliation></author><author><name sortKey="Arwood, Meghan" sort="Arwood, Meghan" uniqKey="Arwood M" first="Meghan" last="Arwood">Meghan Arwood</name><affiliation wicri:level="2"><nlm:affiliation>Tabula Rasa HealthCare Precision Pharmacotherapy Research & Development Institute, Orlando, Florida, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Tabula Rasa HealthCare Precision Pharmacotherapy Research & Development Institute, Orlando, Florida</wicri:regionArea><placeName><region type="state">Floride</region></placeName></affiliation></author><author><name sortKey="Cicali, Brian" sort="Cicali, Brian" uniqKey="Cicali B" first="Brian" last="Cicali">Brian Cicali</name><affiliation wicri:level="2"><nlm:affiliation>College of Pharmacy, Lake Nona Campus, University of Florida, Orlando, Florida, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>College of Pharmacy, Lake Nona Campus, University of Florida, Orlando, Florida</wicri:regionArea><placeName><region type="state">Floride</region></placeName></affiliation></author><author><name sortKey="Turgeon, Jacques" sort="Turgeon, Jacques" uniqKey="Turgeon J" first="Jacques" last="Turgeon">Jacques Turgeon</name><affiliation wicri:level="2"><nlm:affiliation>Tabula Rasa HealthCare Precision Pharmacotherapy Research & Development Institute, Orlando, Florida, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Tabula Rasa HealthCare Precision Pharmacotherapy Research & Development Institute, Orlando, Florida</wicri:regionArea><placeName><region type="state">Floride</region></placeName></affiliation><affiliation wicri:level="1"><nlm:affiliation>Faculty of Pharmacy, Université de Montréal, Montreal, Quebec, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Faculty of Pharmacy, Université de Montréal, Montreal, Quebec</wicri:regionArea><wicri:noRegion>Quebec</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2021">2021</date><idno type="RBID">pubmed:32888379</idno><idno type="pmid">32888379</idno><idno type="doi">10.1111/cts.12882</idno><idno type="pmc">PMC7877829</idno><idno type="wicri:Area/Main/Corpus">000C89</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000C89</idno><idno type="wicri:Area/Main/Curation">000C89</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000C89</idno><idno type="wicri:Area/Main/Exploration">000C89</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Risk Assessment of Drug-Induced Long QT Syndrome for Some COVID-19 Repurposed Drugs.</title><author><name sortKey="Michaud, Veronique" sort="Michaud, Veronique" uniqKey="Michaud V" first="Veronique" last="Michaud">Veronique Michaud</name><affiliation wicri:level="2"><nlm:affiliation>Tabula Rasa HealthCare Precision Pharmacotherapy Research & Development Institute, Orlando, Florida, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Tabula Rasa HealthCare Precision Pharmacotherapy Research & Development Institute, Orlando, Florida</wicri:regionArea><placeName><region type="state">Floride</region></placeName></affiliation><affiliation wicri:level="1"><nlm:affiliation>Faculty of Pharmacy, Université de Montréal, Montreal, Quebec, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Faculty of Pharmacy, Université de Montréal, Montreal, Quebec</wicri:regionArea><wicri:noRegion>Quebec</wicri:noRegion></affiliation></author><author><name sortKey="Dow, Pamela" sort="Dow, Pamela" uniqKey="Dow P" first="Pamela" last="Dow">Pamela Dow</name><affiliation wicri:level="2"><nlm:affiliation>Tabula Rasa HealthCare Precision Pharmacotherapy Research & Development Institute, Orlando, Florida, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Tabula Rasa HealthCare Precision Pharmacotherapy Research & Development Institute, Orlando, Florida</wicri:regionArea><placeName><region type="state">Floride</region></placeName></affiliation></author><author><name sortKey="Al Rihani, Sweilem B" sort="Al Rihani, Sweilem B" uniqKey="Al Rihani S" first="Sweilem B" last="Al Rihani">Sweilem B. Al Rihani</name><affiliation wicri:level="2"><nlm:affiliation>Tabula Rasa HealthCare Precision Pharmacotherapy Research & Development Institute, Orlando, Florida, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Tabula Rasa HealthCare Precision Pharmacotherapy Research & Development Institute, Orlando, Florida</wicri:regionArea><placeName><region type="state">Floride</region></placeName></affiliation></author><author><name sortKey="Deodhar, Malavika" sort="Deodhar, Malavika" uniqKey="Deodhar M" first="Malavika" last="Deodhar">Malavika Deodhar</name><affiliation wicri:level="2"><nlm:affiliation>Tabula Rasa HealthCare Precision Pharmacotherapy Research & Development Institute, Orlando, Florida, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Tabula Rasa HealthCare Precision Pharmacotherapy Research & Development Institute, Orlando, Florida</wicri:regionArea><placeName><region type="state">Floride</region></placeName></affiliation></author><author><name sortKey="Arwood, Meghan" sort="Arwood, Meghan" uniqKey="Arwood M" first="Meghan" last="Arwood">Meghan Arwood</name><affiliation wicri:level="2"><nlm:affiliation>Tabula Rasa HealthCare Precision Pharmacotherapy Research & Development Institute, Orlando, Florida, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Tabula Rasa HealthCare Precision Pharmacotherapy Research & Development Institute, Orlando, Florida</wicri:regionArea><placeName><region type="state">Floride</region></placeName></affiliation></author><author><name sortKey="Cicali, Brian" sort="Cicali, Brian" uniqKey="Cicali B" first="Brian" last="Cicali">Brian Cicali</name><affiliation wicri:level="2"><nlm:affiliation>College of Pharmacy, Lake Nona Campus, University of Florida, Orlando, Florida, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>College of Pharmacy, Lake Nona Campus, University of Florida, Orlando, Florida</wicri:regionArea><placeName><region type="state">Floride</region></placeName></affiliation></author><author><name sortKey="Turgeon, Jacques" sort="Turgeon, Jacques" uniqKey="Turgeon J" first="Jacques" last="Turgeon">Jacques Turgeon</name><affiliation wicri:level="2"><nlm:affiliation>Tabula Rasa HealthCare Precision Pharmacotherapy Research & Development Institute, Orlando, Florida, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Tabula Rasa HealthCare Precision Pharmacotherapy Research & Development Institute, Orlando, Florida</wicri:regionArea><placeName><region type="state">Floride</region></placeName></affiliation><affiliation wicri:level="1"><nlm:affiliation>Faculty of Pharmacy, Université de Montréal, Montreal, Quebec, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Faculty of Pharmacy, Université de Montréal, Montreal, Quebec</wicri:regionArea><wicri:noRegion>Quebec</wicri:noRegion></affiliation></author></analytic><series><title level="j">Clinical and translational science</title><idno type="eISSN">1752-8062</idno><imprint><date when="2021" type="published">2021</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiviral Agents (adverse effects)</term><term>Azithromycin (adverse effects)</term><term>COVID-19 (drug therapy)</term><term>Drug Repositioning (MeSH)</term><term>Humans (MeSH)</term><term>Hydroxychloroquine (adverse effects)</term><term>Long QT Syndrome (chemically induced)</term><term>Risk Assessment (MeSH)</term><term>SARS-CoV-2 (MeSH)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Antiviraux (effets indésirables)</term><term>Appréciation des risques (MeSH)</term><term>Azithromycine (effets indésirables)</term><term>Humains (MeSH)</term><term>Hydroxychloroquine (effets indésirables)</term><term>Repositionnement des médicaments (MeSH)</term><term>Syndrome du QT long (induit chimiquement)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antiviral Agents</term><term>Azithromycin</term><term>Hydroxychloroquine</term></keywords><keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Long QT Syndrome</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>COVID-19</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Antiviraux</term><term>Azithromycine</term><term>Hydroxychloroquine</term></keywords><keywords scheme="MESH" qualifier="induit chimiquement" xml:lang="fr"><term>Syndrome du QT long</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Drug Repositioning</term><term>Humans</term><term>Risk Assessment</term><term>SARS-CoV-2</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Appréciation des risques</term><term>Humains</term><term>Repositionnement des médicaments</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The risk-benefit ratio associated with the use of repurposed drugs to treat severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2)-related infectious coronavirus disease 2019 (COVID-19) is complicated because benefits are awaited, not proven. A thorough literature search was conducted to source information on the pharmacological properties of 5 drugs and 1 combination (azithromycin, chloroquine, favipiravir, hydroxychloroquine, remdesivir, and lopinavir/ritonavir) repurposed to treat COVID-19. A risk assessment of drug-induced long QT syndrome (LQTS) associated with COVID-19 repurposed drugs was performed and compared with 23 well-known torsadogenic and 10 low torsadogenic risk compounds. Computer calculations were performed using pharmacokinetic and pharmacodynamic data, including affinity to block the rapid component of the delayed rectifier cardiac potassium current (I<sub>Kr</sub> ) encoded by the human ether-a-go-go gene (hERG), propensity to prolong cardiac repolarization (QT interval) and cause torsade de pointes (TdP). Seven different LQTS indices were calculated and compared. The US Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) database was queried with specific key words relating to arrhythmogenic events. Estimators of LQTS risk levels indicated a very high or moderate risk for all COVID-19 repurposed drugs with the exception for azithromycin, although cases of TdP have been reported with this drug. There was excellent agreement among the various indices used to assess risk of drug-induced LQTS for the 6 repurposed medications and 23 torsadogenic compounds. Based on our results, monitoring of the QT interval shall be performed when some COVID-19 repurposed drugs are used, as such monitoring is possible for hospitalized patients or with the use of biodevices for outpatients.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32888379</PMID><DateCompleted><Year>2021</Year><Month>02</Month><Day>22</Day></DateCompleted><DateRevised><Year>2021</Year><Month>02</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1752-8062</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>1</Issue><PubDate><Year>2021</Year><Month>01</Month></PubDate></JournalIssue><Title>Clinical and translational science</Title><ISOAbbreviation>Clin Transl Sci</ISOAbbreviation></Journal><ArticleTitle>Risk Assessment of Drug-Induced Long QT Syndrome for Some COVID-19 Repurposed Drugs.</ArticleTitle><Pagination><MedlinePgn>20-28</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/cts.12882</ELocationID><Abstract><AbstractText>The risk-benefit ratio associated with the use of repurposed drugs to treat severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2)-related infectious coronavirus disease 2019 (COVID-19) is complicated because benefits are awaited, not proven. A thorough literature search was conducted to source information on the pharmacological properties of 5 drugs and 1 combination (azithromycin, chloroquine, favipiravir, hydroxychloroquine, remdesivir, and lopinavir/ritonavir) repurposed to treat COVID-19. A risk assessment of drug-induced long QT syndrome (LQTS) associated with COVID-19 repurposed drugs was performed and compared with 23 well-known torsadogenic and 10 low torsadogenic risk compounds. Computer calculations were performed using pharmacokinetic and pharmacodynamic data, including affinity to block the rapid component of the delayed rectifier cardiac potassium current (I<sub>Kr</sub> ) encoded by the human ether-a-go-go gene (hERG), propensity to prolong cardiac repolarization (QT interval) and cause torsade de pointes (TdP). Seven different LQTS indices were calculated and compared. The US Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) database was queried with specific key words relating to arrhythmogenic events. Estimators of LQTS risk levels indicated a very high or moderate risk for all COVID-19 repurposed drugs with the exception for azithromycin, although cases of TdP have been reported with this drug. There was excellent agreement among the various indices used to assess risk of drug-induced LQTS for the 6 repurposed medications and 23 torsadogenic compounds. Based on our results, monitoring of the QT interval shall be performed when some COVID-19 repurposed drugs are used, as such monitoring is possible for hospitalized patients or with the use of biodevices for outpatients.</AbstractText><CopyrightInformation>© 2020 Tabula Rasa Healthcare, Inc. Clinical and Translational Science published by Wiley Periodicals LLC on behalf of the American Society for Clinical Pharmacology and Therapeutics.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Michaud</LastName><ForeName>Veronique</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Tabula Rasa HealthCare Precision Pharmacotherapy Research & Development Institute, Orlando, Florida, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Pharmacy, Université de Montréal, Montreal, Quebec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dow</LastName><ForeName>Pamela</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Tabula Rasa HealthCare Precision Pharmacotherapy Research & Development Institute, Orlando, Florida, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Al Rihani</LastName><ForeName>Sweilem B</ForeName><Initials>SB</Initials><AffiliationInfo><Affiliation>Tabula Rasa HealthCare Precision Pharmacotherapy Research & Development Institute, Orlando, Florida, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deodhar</LastName><ForeName>Malavika</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Tabula Rasa HealthCare Precision Pharmacotherapy Research & Development Institute, Orlando, Florida, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arwood</LastName><ForeName>Meghan</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Tabula Rasa HealthCare Precision Pharmacotherapy Research & Development Institute, Orlando, Florida, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cicali</LastName><ForeName>Brian</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>College of Pharmacy, Lake Nona Campus, University of Florida, Orlando, Florida, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Turgeon</LastName><ForeName>Jacques</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Tabula Rasa HealthCare Precision Pharmacotherapy Research & Development Institute, Orlando, Florida, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Pharmacy, Université de Montréal, Montreal, Quebec, Canada.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>11</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Clin Transl Sci</MedlineTA><NlmUniqueID>101474067</NlmUniqueID><ISSNLinking>1752-8054</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>4QWG6N8QKH</RegistryNumber><NameOfSubstance UI="D006886">Hydroxychloroquine</NameOfSubstance></Chemical><Chemical><RegistryNumber>83905-01-5</RegistryNumber><NameOfSubstance UI="D017963">Azithromycin</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Protocol" UI="C000705127">COVID-19 drug treatment</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017963" MajorTopicYN="N">Azithromycin</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058492" MajorTopicYN="Y">Drug Repositioning</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006886" MajorTopicYN="N">Hydroxychloroquine</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008133" MajorTopicYN="N">Long QT Syndrome</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>06</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>09</Month><Day>01</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>9</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>2</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>9</Month><Day>5</Day><Hour>8</Hour><Minute>34</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32888379</ArticleId><ArticleId IdType="doi">10.1111/cts.12882</ArticleId><ArticleId IdType="pmc">PMC7877829</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Eur J Pharmacol. 2004 Jan 19;484(1):41-8</Citation><ArticleIdList><ArticleId IdType="pubmed">14729380</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Physiol. 2017 Nov 16;8:934</Citation><ArticleIdList><ArticleId IdType="pubmed">29201009</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Drug Discov. 2010 Mar;9(3):203-14</Citation><ArticleIdList><ArticleId IdType="pubmed">20168317</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacotherapy. 1992;12(3):161-73</Citation><ArticleIdList><ArticleId IdType="pubmed">1319048</ArticleId></ArticleIdList></Reference><Reference><Citation>Cardiovasc Res. 2003 Apr 1;58(1):32-45</Citation><ArticleIdList><ArticleId IdType="pubmed">12667944</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Pharmacother. 2008 Jul;42(7):1048-59</Citation><ArticleIdList><ArticleId IdType="pubmed">18577765</ArticleId></ArticleIdList></Reference><Reference><Citation>Fed Regist. 2005 Oct 20;70(202):61134-5</Citation><ArticleIdList><ArticleId IdType="pubmed">16237860</ArticleId></ArticleIdList></Reference><Reference><Citation>AAPS J. 2018 Jul 11;20(5):83</Citation><ArticleIdList><ArticleId IdType="pubmed">29995258</ArticleId></ArticleIdList></Reference><Reference><Citation>Antimicrob Agents Chemother. 2002 Apr;46(4):977-81</Citation><ArticleIdList><ArticleId IdType="pubmed">11897578</ArticleId></ArticleIdList></Reference><Reference><Citation>Pacing Clin Electrophysiol. 2007 Dec;30(12):1579-82</Citation><ArticleIdList><ArticleId IdType="pubmed">18070319</ArticleId></ArticleIdList></Reference><Reference><Citation>J Antimicrob Chemother. 1990 Jan;25 Suppl A:73-82</Citation><ArticleIdList><ArticleId IdType="pubmed">2154441</ArticleId></ArticleIdList></Reference><Reference><Citation>Sci Rep. 2013;3:2100</Citation><ArticleIdList><ArticleId IdType="pubmed">23812503</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Antimicrob Agents. 2020 Jul;56(1):105949</Citation><ArticleIdList><ArticleId IdType="pubmed">32205204</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Pharmacokinet. 1996 Oct;31(4):257-74</Citation><ArticleIdList><ArticleId IdType="pubmed">8896943</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Pharmacol Ther. 2000 Mar;67(3):237-41</Citation><ArticleIdList><ArticleId IdType="pubmed">10741626</ArticleId></ArticleIdList></Reference><Reference><Citation>Am Heart J. 2014 Mar;167(3):292-300</Citation><ArticleIdList><ArticleId IdType="pubmed">24576511</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Toxicol (Phila). 2006;44(2):173-5</Citation><ArticleIdList><ArticleId IdType="pubmed">16615675</ArticleId></ArticleIdList></Reference><Reference><Citation>Heart Rhythm. 2020 Sep;17(9):1456-1462</Citation><ArticleIdList><ArticleId IdType="pubmed">32244059</ArticleId></ArticleIdList></Reference><Reference><Citation>Fed Regist. 2005 Oct 20;70(202):61133-4</Citation><ArticleIdList><ArticleId IdType="pubmed">16237859</ArticleId></ArticleIdList></Reference><Reference><Citation>Circ Cardiovasc Qual Outcomes. 2013 Jul;6(4):479-87</Citation><ArticleIdList><ArticleId IdType="pubmed">23716032</ArticleId></ArticleIdList></Reference><Reference><Citation>J Chem Inf Model. 2018 Apr 23;58(4):867-878</Citation><ArticleIdList><ArticleId IdType="pubmed">29547274</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2010 Jan 12;107(2):882-7</Citation><ArticleIdList><ArticleId IdType="pubmed">20080770</ArticleId></ArticleIdList></Reference><Reference><Citation>Drug Metab Dispos. 2003 Jun;31(6):748-54</Citation><ArticleIdList><ArticleId IdType="pubmed">12756207</ArticleId></ArticleIdList></Reference><Reference><Citation>Heart. 2003 Nov;89(11):1363-72</Citation><ArticleIdList><ArticleId IdType="pubmed">14594906</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Clin Microbiol Antimicrob. 2020 Jan 22;19(1):3</Citation><ArticleIdList><ArticleId IdType="pubmed">31969147</ArticleId></ArticleIdList></Reference><Reference><Citation>J Pharmacol Toxicol Methods. 2016 Sep-Oct;81:15-20</Citation><ArticleIdList><ArticleId IdType="pubmed">27282641</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Commun. 2020 Jan 10;11(1):222</Citation><ArticleIdList><ArticleId IdType="pubmed">31924756</ArticleId></ArticleIdList></Reference><Reference><Citation>J Pharm Sci. 2011 Jun;100(6):2469-81</Citation><ArticleIdList><ArticleId IdType="pubmed">21491454</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Cardiol. 2008 Jul 4;127(2):e80-2</Citation><ArticleIdList><ArticleId IdType="pubmed">17590456</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Med. 2020 Aug 10;9(8):</Citation><ArticleIdList><ArticleId IdType="pubmed">32785135</ArticleId></ArticleIdList></Reference><Reference><Citation>One Health. 2020 Mar 27;9:100128</Citation><ArticleIdList><ArticleId IdType="pubmed">32258351</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Pharmacokinet. 2003;42(3):223-82</Citation><ArticleIdList><ArticleId IdType="pubmed">12603174</ArticleId></ArticleIdList></Reference><Reference><Citation>J Cardiovasc Pharmacol Ther. 1999 Jul;4(3):143-150</Citation><ArticleIdList><ArticleId IdType="pubmed">10684535</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2005 Feb 19-25;365(9460):682-6</Citation><ArticleIdList><ArticleId IdType="pubmed">15721475</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2001 Mar 29;344(13):984-96</Citation><ArticleIdList><ArticleId IdType="pubmed">11274626</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS Comput Biol. 2011 May;7(5):e1002061</Citation><ArticleIdList><ArticleId IdType="pubmed">21637795</ArticleId></ArticleIdList></Reference><Reference><Citation>J Pharmacol Exp Ther. 2002 Oct;303(1):218-25</Citation><ArticleIdList><ArticleId IdType="pubmed">12235254</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Pharmacol Ther. 2012 Feb;91(2):281-8</Citation><ArticleIdList><ArticleId IdType="pubmed">22205197</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed><affiliations><list><country><li>Canada</li><li>États-Unis</li></country><region><li>Floride</li></region></list><tree><country name="États-Unis"><region name="Floride"><name sortKey="Michaud, Veronique" sort="Michaud, Veronique" uniqKey="Michaud V" first="Veronique" last="Michaud">Veronique Michaud</name></region><name sortKey="Al Rihani, Sweilem B" sort="Al Rihani, Sweilem B" uniqKey="Al Rihani S" first="Sweilem B" last="Al Rihani">Sweilem B. Al Rihani</name><name sortKey="Arwood, Meghan" sort="Arwood, Meghan" uniqKey="Arwood M" first="Meghan" last="Arwood">Meghan Arwood</name><name sortKey="Cicali, Brian" sort="Cicali, Brian" uniqKey="Cicali B" first="Brian" last="Cicali">Brian Cicali</name><name sortKey="Deodhar, Malavika" sort="Deodhar, Malavika" uniqKey="Deodhar M" first="Malavika" last="Deodhar">Malavika Deodhar</name><name sortKey="Dow, Pamela" sort="Dow, Pamela" uniqKey="Dow P" first="Pamela" last="Dow">Pamela Dow</name><name sortKey="Turgeon, Jacques" sort="Turgeon, Jacques" uniqKey="Turgeon J" first="Jacques" last="Turgeon">Jacques Turgeon</name></country><country name="Canada"><noRegion><name sortKey="Michaud, Veronique" sort="Michaud, Veronique" uniqKey="Michaud V" first="Veronique" last="Michaud">Veronique Michaud</name></noRegion><name sortKey="Turgeon, Jacques" sort="Turgeon, Jacques" uniqKey="Turgeon J" first="Jacques" last="Turgeon">Jacques Turgeon</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000188 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000188 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidChloroV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:32888379
|texte= Risk Assessment of Drug-Induced Long QT Syndrome for Some COVID-19 Repurposed Drugs.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:32888379" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a CovidChloroV1
| This area was generated with Dilib version V0.6.38. |  |